The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MK-485     (2S)-3-(3,4-dihydroxyphenyl)- 2-hydrazinyl...

Synonyms: Lodosyn (TN), CHEBI:3395, CHEMBL1200748, SureCN1217887, LS-77200, ...
This record was replaced with 34359.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MK 486


Psychiatry related information on MK 486

  • However, 10 patients showed a slight decrease of this improvement after 6 months; 3 had to be put back on standard Sinemet because of hallucinations (1) or accentuation of dyskinesia and akinesia (2) [6].

High impact information on MK 486


Chemical compound and disease context of MK 486


Biological context of MK 486

  • Despite a strong relationship between reductions in levodopa AUC and reductions in Sinemet efficacy (r = 0.83, P less than 0.01), the average reduction in Sinemet's efficacy associated with ferrous sulphate did not achieve statistical significance (P = 0.055) [16].
  • The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing [17].
  • The kinetics of Sinemet CR are limited by rates of absorption (which depend on the dose administered), the conformation of the tablet, and daily variations in the patterns of gastric emptying (influenced by the presence or absence of food) [18].

Anatomical context of MK 486


Associations of MK 486 with other chemical compounds


Gene context of MK 486

  • COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet) [28].
  • Sinemet caused significantly greater placebo-corrected increases in GH and HVA during early as compared with late abstinence [29].
  • During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep [30].
  • The only significant difference in these parameters between the CR4 and standard Sinemet treatment periods in the entire group was a decrease in hours of dyskinesia per day [31].
  • What to do when Sinemet fails: Part one [32].

Analytical, diagnostic and therapeutic context of MK 486


  1. Skin rash associated with Sinemet 25/100. Goetz, C.G. N. Engl. J. Med. (1983) [Pubmed]
  2. Unsuccessful treatment of severe pain from bone metastasis with Sinemet 25/100. Sjølin, S.U., Trykker, H. N. Engl. J. Med. (1985) [Pubmed]
  3. Sympathetic cardioneuropathy in dysautonomias. Goldstein, D.S., Holmes, C., Cannon, R.O., Eisenhofer, G., Kopin, I.J. N. Engl. J. Med. (1997) [Pubmed]
  4. Sinemet and the treatment of Parkinsonism. Boshes, B. Ann. Intern. Med. (1981) [Pubmed]
  5. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Miyoshi, Y., Zhang, Z., Ovadia, A., Lapchak, P.A., Collins, F., Hilt, D., Lebel, C., Kryscio, R., Gash, D.M. Ann. Neurol. (1997) [Pubmed]
  6. Experiences with Sinemet CR in the Paracelsus-Elena-Klinik. Ulm, G., Gerdes, U., Haagen, K. Neurology (1989) [Pubmed]
  7. Sensorimotor disinhibition in Parkinson's disease: effects of levodopa. Caligiuri, M.P., Heindel, W.C., Lohr, J.B. Ann. Neurol. (1992) [Pubmed]
  8. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. Diamond, S.G., Markham, C.H., Treciokas, L.J. Ann. Neurol. (1978) [Pubmed]
  9. The use of Sinemet CR in the management of mild to moderate Parkinson's disease. Rodnitzky, R.L. Neurology (1992) [Pubmed]
  10. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Yeh, K.C., August, T.F., Bush, D.F., Lasseter, K.C., Musson, D.G., Schwartz, S., Smith, M.E., Titus, D.C. Neurology (1989) [Pubmed]
  11. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Goetz, C.G., Tanner, C.M., Gilley, D.W., Klawans, H.L. Neurology (1989) [Pubmed]
  12. Double-blind trial of pergolide for Parkinson's disease. Diamond, S.G., Markham, C.H., Treciokas, L.J. Neurology (1985) [Pubmed]
  13. Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency. Goldstein, D.S., Hahn, S.H., Holmes, C., Tifft, C., Harvey-White, J., Milstien, S., Kaufman, S. J. Neurochem. (1995) [Pubmed]
  14. Pergolide: long-term use in Parkinson's disease. Ahlskog, J.E., Muenter, M.D. Mayo Clin. Proc. (1988) [Pubmed]
  15. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming, S.M., Delville, Y., Schallert, T. Behav. Brain Res. (2005) [Pubmed]
  16. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease. Campbell, N.R., Rankine, D., Goodridge, A.E., Hasinoff, B.B., Kara, M. British journal of clinical pharmacology. (1990) [Pubmed]
  17. The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. Costa, E.R., Weinhold, P., Tayrose, G.A., Hooker, J.A., Dahners, L.E. Journal of orthopaedic trauma. (2006) [Pubmed]
  18. Pharmacokinetics of continuous-release carbidopa/levodopa. Sage, J.I., Mark, M.H. Clinical neuropharmacology. (1994) [Pubmed]
  19. Sinemet and thyroid function in Parkinson disease. Wingert, T.D., Hershman, J.M. Neurology (1979) [Pubmed]
  20. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. Hickey, M.A., Reynolds, G.P., Morton, A.J. J. Neurochem. (2002) [Pubmed]
  21. A new syndrome of axial muscle rigidity associated with etretinate therapy. Albin, R.L., Silverman, A.K., Ellis, C.N., Voorhees, J.J., Albers, J.W. Mov. Disord. (1988) [Pubmed]
  22. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Bédard, P.J., Di Paolo, T., Falardeau, P., Boucher, R. Brain Res. (1986) [Pubmed]
  23. Levodopa can worsen tremor associated with dystonia. Hensman, D.J., Bain, P.G. Mov. Disord. (2006) [Pubmed]
  24. Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease. Boomsma, F., van den Meiracker, A., Man in 't Veld, A., Schalekamp, M. Life Sci. (1995) [Pubmed]
  25. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. Larsen, K.R., Dajani, E.Z., Dajani, N.E., Dayton, M.T., Moore, J.G. Dig. Dis. Sci. (1998) [Pubmed]
  26. Parkinson's disease: Cogentin with Sinemet, a better response. Tourtellotte, W.W., Potvin, A.R., Syndulko, K., Hirsch, S.B., Gilden, E.R., Potvin, J.H., Hansch, E.C. Prog. Neuropsychopharmacol. Biol. Psychiatry (1982) [Pubmed]
  27. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease. Martinez-Campos, A., Giovannini, P., Novelli, A., Cocchi, D., Caraceni, T., Müller, E.E. Acta Endocrinol. (1982) [Pubmed]
  28. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). Jorga, K.M., Nicholl, D.J. British journal of clinical pharmacology. (1999) [Pubmed]
  29. Dopaminergic responsivity during cocaine abstinence: a pilot study. McDougle, C.J., Price, L.H., Palumbo, J.M., Kosten, T.R., Heninger, G.R., Kleber, H.D. Psychiatry research. (1992) [Pubmed]
  30. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease. Bell, R.D., Carruth, A., Rosenberg, R.N., Boyar, R.M. J. Clin. Endocrinol. Metab. (1978) [Pubmed]
  31. Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease. Factor, S.A., Sanchez-Ramos, J.R., Weiner, W.J., Ingenito, A.M. J. Neurol. Neurosurg. Psychiatr. (1989) [Pubmed]
  32. What to do when Sinemet fails: Part one. Klawans, H.L. Clinical neuropharmacology. (1984) [Pubmed]
  33. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. Feldman, R.G., Mosbach, P.A., Kelly, M.R., Thomas, C.A., Saint Hilaire, M.H. Neurology (1989) [Pubmed]
  34. Gastrointestinal transit of Sinemet CR in healthy volunteers. Wilding, I.R., Davis, S.S., Melia, C.D., Hardy, J.G., Evans, D.F., Short, A.H., Sparrow, R.A. Neurology (1989) [Pubmed]
  35. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group. Bush, D.F., Liss, C.L., Morton, A. Neurology (1989) [Pubmed]
  36. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Hutton, J.T., Morris, J.L., Román, G.C., Imke, S.C., Elias, J.W. Arch. Neurol. (1988) [Pubmed]
WikiGenes - Universities